Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
Geneva, Switzerland, May 2, 2024 “ STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...
STALICLA Appoints Dr. Thomas Blaettler, MD
Stalicla Secures $17.4 Million in Series B Financing
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
Novartis has kept the faith in mavoglurant even after the therapy flunked a trial in a genetic disorder, and, now, fellow Swiss drug developer Stalicla has signed off on $270 million in biobucks to take the asset into phase 3.
GENEVA, Oct. 10, 2022 /PRNewswire/ -- STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).